History
A list of downloadable documents created during development.
Final appraisal determination
Prostate cancer (advanced, hormone dependent) - degarelix depot: appraisal consultation 2
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: appraisal consultation 2
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: appraisal consultation document
-
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: committee papers information
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: committee papers (PDF 334 KB)
Prostate cancer (advanced, hormone dependent) - degarelix depot: appeal
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: appeal
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: appeal decision
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: appeal decision (PDF 303 KB)
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: notice of appeal information
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: appeal announcement information
-
Ferring Pharmaceuticals Ltd
-
Appeals received
-
-
Initial scrutiny letter
-
-
Response to scrutiny letter
-
-
Final scrutiny letter
-
-
British Uro-Oncology Group
-
Appeals received
-
-
Initial scrutiny letter
-
-
Response to scrutiny letter
-
-
Final scrutiny letter
-
-
Tackle Prostate Cancer
-
Appeals received
-
-
Initial scrutiny letter
-
-
Response to scrutiny letter
-
-
Final scrutiny letter
-
-
Response to final scrutiny letter
-
-
Vice Chair of NICE's final response
-
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: final appraisal determination
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: final appraisal determination
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: FAD document
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: FAD document (PDF 475 KB)
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: evaluation report information
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: evaluation report (PDF 4.93 MB)
Prostate cancer (advanced, hormone dependent) - degarelix depot: appraisal consultation
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: appraisal consultation
-
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: evaluation report information
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: evaluation report (PDF 12.21 MB)
Prostate cancer (advanced, hormone dependent) - degarelix depot: equality impact assessment form - scoping
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: equality impact assessment form - scoping
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: response to consultee and commentator comments on the draft scope and provisional matrix
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: response to consultee and commentator comments on the draft scope and provisional matrix
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: final matrix
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: final matrix
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: final matrix (PDF 101 KB)
Prostate cancer (advanced, hormone dependent) - degarelix depot: final scope
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: final scope
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: final scope (PDF 100 KB)
Prostate cancer (advanced, hormone dependent) - degarelix depot: draft scope (pre-referral)
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: draft scope (pre-referral)
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: provisional matrix (pre-referral)
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: provisional matrix (pre-referral)
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: equality impact assessment guidance development
-
Prostate cancer (advanced, hormone dependent) - degarelix depot: equality impact assessment guidance development
-